2025 ISAKOS Congress in Munich, Germany

ISAKOS Congress Call for Abstracts


ACCME Standards

ACCME Standards for Integrity and Independence in Accredited Continuing Education require providers to mitigate relevant financial relationships to prevent commercial bias and disclose the presence or absence of all relevant financial relationships to learners prior to the activity. According to Standard 3.2 of the ACCME Standards for Integrity and Independence in Accredited Continuing Education, “Owners and employees of ineligible companies must be excluded from controlling content or participating as planners or faculty in accredited education”. The Presenting Author of any accepted abstract /poster cannot be employed by an ACCME- defined ineligible company*. Employees of ineligible companies are prohibited from having any role in the planning or implementation of CME activities related to the ineligible company’s business lines or products.

*An ineligible company (formerly called a commercial interest) is one whose primary business is producing, marketing, re-selling, or distributing health care products used by, on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.

You may be required to edit your submission if it is found to be noncompliant with these standards:

  • ACCME and HIPPA Compliance- All individually identifiable health information regarding a client or patient must be sufficiently edited or modified to ensure HIPPA compliance.
  • Presentations must give a balanced view of therapeutic options. All recommendations for patient care must be based on current science, evidence, and clinical reasoning.
  • New and evolving topics must be clearly identified in the presentation slides.
  • Presentations must be free of commercial bias for or against any company, product, drug, or device.
  • Educational materials (abstracts, presentations, videos, and photos) must not include:
    • Ineligible companies’ corporate or product logos.
    • Company, product, drug, or device brand/trade names. (generic names should be used)
    • If brand/trade names are listed, there MUST be at least two (2) other names listed to avoid the perception of bias.
    • If only one is listed, it must be proven to be the one and only best product, device, and/or drug available.
  • All logos or brand names visible in photos or videos must be completely covered.
  • All abstracts will be reviewed for compliance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education.

Abstract Submissions Open February 1, 2024 | Deadline September 1, 2024

Don't miss your chance to submit Abstracts for the ISAKOS 2025 Congress being offered live in Munich, Germany June 8-11, 2025. Abstracts are being reviewed and accepted for in-person podium presentations and electronic and in-person posters, from presenters around the world who would like to join their colleagues in Munich. In addition, exceptional abstracts will be considered for several ISAKOS Awards for outstanding clinical or laboratory research, which will be presented at this live event.

Instructions for submitting an abstract:

  • Log-in using the presenting author’s email and password for ISAKOS. If a record does not exist for the presenting author, you will be prompted to create a new record.
  • You must then create or update your Financial Disclosure Statement with AAOS to be current within 24 months. Upon completion, you will return to the abstract submission portal at ISAKOS.
  • Complete contact information for the presenting and other authors, including the institution of research. It is helpful to have the ISAKOS ID numbers for as many authors as possible. You may email isakos@isakos.com to obtain an author’s ISAKOS ID number—please do not make duplicate records.
  • Complete the American Food and Drug Administration (FDA) Statement and Copyright License Agreement on behalf of all authors.
  • Provide the abstract title in proper title case for publishing, e.g., The Science of Orthopaedic Surgery.
  • Enter the plain abstract text in the provided text box. Please note, graphics and tables are not accepted. There is a maximum of 500 words.

Once the abstract is submitted by the presenting author, any other authors will be notified to complete their disclosures through AAOS. Abstracts will not be considered until all disclosures are completed. Please ensure that the same email is used for both ISAKOS and AAOS accounts.

Abstract Review

Following the submission deadline, all abstracts are blindly reviewed by committees of qualified orthopaedic surgeons.

Notification of Results

The presenting author will receive a letter of acceptance or rejection via email for this abstract by November 30, 2024.


Abstract Submission Guidelines

Author warranty: Persons submitting an abstract to ISAKOS do so with the understanding that they and all the authors listed on the abstract will abide by the guidelines, conditions, deadlines, policies, and decisions of the ISAKOS Board of Directors and Program Committee.

  1. The deadline for abstract submission is September 1, 2024 at 11:59 P.M. Pacific Standard Time. Abstracts will not be accepted after that time.
  2. Abstracts must be submitted from the ISAKOS account of the Presenting Author.
  3. Authors do not have to be ISAKOS members to submit an abstract.
  4. There is no limit to the number of abstracts that can be submitted for consideration; however each presenting author will be limited to no more than two paper presentations during the ISAKOS Congress.
  5. If the abstract is accepted for podium presentation, all presenters must speak in English, and be prepared to answer questions from the audience in English
  6. All presenters, co-authors, faculty members, etc. who will attend the Congress are expected to register for the meeting and pay all registration and travel costs. No exceptions are made. If attendance is dependent on outside funding, please secure financial assistance before submitting an abstract.
  7. Abstracts are only accepted for consideration via the online abstract application form. Abstracts submitted in any other fashion will not be considered for presentation.
  8. The ISAKOS Program Committee will make final decisions on the mode of presentation. Efforts will be made to comply with the stated preference of podium or poster presentation.
  9. Presenting Authors and other authors must complete a Financial Disclosure Statement through AAOS, as well as an American Food and Drug Administration statement within the abstract application.
    *Although ISAKOS is an international society, it receives continuing medical education accreditation and is planned and implemented with the essential areas and policies of the Accreditation Council for Continuing Medical Education (ACCME).
  10. Presenting Authors must complete a Copyright License Agreement so the chosen abstracts can be published by ISAKOS. Channels may include the ISAKOS and Journal of ISAKOS websites.
  11. Abstract Text must be a maximum of 500 words.

Abstract Grading Criteria

Abstracts are graded on a scale from 0.0 to 12.0 (12.0 being the best) based on the following:

  • Scientific Merit (0-6, with 6 points max)
    • Is the problem clearly stated?
    • Are the statistics sound?
    • Are there adequate numbers of subjects?
    • How is the methodology? {are there controls?, is this prospective vs. retrospective?}
    • Is the abstract clear / well written and are the results clear?
    • Are the conclusions supported by the results?
  • Originality of Project (0-2)
  • Clinical Usefulness (0-2)
  • Level of Interest to ISAKOS Members (0-2)